TY - JOUR
T1 - Facts and hopes in immunotherapy of soft-tissue sarcomas
AU - Martín-Broto, Javier
AU - Moura, David S.
AU - van Tine, Brian A.
N1 - Funding Information:
J. Martín-Broto reports grants, personal fees, and other from PharmaMar (research funding for clinical studies; institutional) and Eisai (research funding for clinical studies; institutional), grants from IMMIX Biopharma, grants and other from Novartis (research funding for clinical studies; institutional), personal fees and other from Eli Lilly (research funding for clinical studies; institutional) and Bayer (research funding for clinical studies; institutional), and other from AROG (research funding for clinical studies; institutional), Lixte (research funding for clinical studies; institutional), Karyopharm (research funding for clinical studies; institutional), Deciphera (research funding for clinical studies; institutional), GlaxoSmithKline (research funding for clinical studies; institutional), Blueprint (research funding for clinical studies; institutional), Nektar (research funding for clinical studies; institutional), Forma (research funding for clinical studies; institutional), Amgen (research funding for clinical studies; institutional), and Daiichi Sankyo (research funding for clinical studies; institutional) outside the submitted work. D.S. Moura reports grants and non-financial support from PharmaMar (institutional grant for preclinical research) and Eisai (institutional grant for preclinical research), grants from Novartis (institutional grant for preclinical research) and Immix Biopharma (institutional grant for preclinical research), and non-financial support from Pfizer, Bayer, and Celgene outside the submitted work. B.A. Van Tine reports personal fees from Lilly (advisory board, speaker bureau), Janssen (advisory board, speaker bureau), Caris (consulting fee/advisory board), Novartis (consultant/adviser/speaker), CytRX (consultant/adviser/speaker), Plexxikon (consultant/adviser/speaker), Epizyme (consultant/adviser/speaker), Daiichi Sankyo (consultant/adviser), Adaptimmune (consultant/adviser/speaker), Bayer (consultant/adviser), Deciphera (consultant), Apexigen (consultant), and Polaris (board member), grants and personal fees from Pfizer (consultant/adviser/ research grant) and GlaxoSmithKline (consultant/research grant/speakers bureau/travel expenses), and grants from Merck (research grant) and Tracon (research grant) outside the submitted work. No other potential conflicts of interest were disclosed.
Funding Information:
B.A. Van Tine was supported by the NCI (RO1CA227115).
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/11/15
Y1 - 2020/11/15
N2 - Sarcomas are mesenchymal tumors, encompassing more than 175 subtypes, each one with their own genetic complexities. As a result, immunotherapy approaches have not been universally successful across the wide range of diverse subtypes. The actual state of science and the current clinical data utilizing immunotherapy within the soft-tissue sarcomas (STS) will be detailed in this review. More precisely, the review will focus on: (i) the role of the immune microenvironment in the development and activity of new therapeutic approaches; (ii) the recent identification of the sarcoma immune class (SIC) groups, especially group SIC E with its B-cell signature that predicts immunotherapy response; (iii) the clinical trials using PD-1 and/or CTLA-4 inhibitors, which serves as reference for response data, (iv) the promising clinical activity from the combination of anti-angiogenics agents with PD-1 inhibitors, (v) the adapted T-cell therapies for synovial sarcoma that target either NY-ESO or MAGEA4; and (vi) the role for localized therapy using the virotherapy T-VEC with PD-1 inhibitors. Herein, we present the facts and the hopes for the patients with sarcoma, as the field is rapidly advancing its understanding of what and where to use the various types of immunotherapies.
AB - Sarcomas are mesenchymal tumors, encompassing more than 175 subtypes, each one with their own genetic complexities. As a result, immunotherapy approaches have not been universally successful across the wide range of diverse subtypes. The actual state of science and the current clinical data utilizing immunotherapy within the soft-tissue sarcomas (STS) will be detailed in this review. More precisely, the review will focus on: (i) the role of the immune microenvironment in the development and activity of new therapeutic approaches; (ii) the recent identification of the sarcoma immune class (SIC) groups, especially group SIC E with its B-cell signature that predicts immunotherapy response; (iii) the clinical trials using PD-1 and/or CTLA-4 inhibitors, which serves as reference for response data, (iv) the promising clinical activity from the combination of anti-angiogenics agents with PD-1 inhibitors, (v) the adapted T-cell therapies for synovial sarcoma that target either NY-ESO or MAGEA4; and (vi) the role for localized therapy using the virotherapy T-VEC with PD-1 inhibitors. Herein, we present the facts and the hopes for the patients with sarcoma, as the field is rapidly advancing its understanding of what and where to use the various types of immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=85099742953&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-3335
DO - 10.1158/1078-0432.CCR-19-3335
M3 - Review article
C2 - 32601077
AN - SCOPUS:85099742953
VL - 26
SP - 5801
EP - 5808
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 22
ER -